Integrative Oncology: An International Perspective from Six Countries

Tolédano, A.; Rao, Santosh; Frenkel, Moshe; Rossi, Elio; Bagot, Jean-Lionel; Theunissen, Ingrid; Díaz-Sáez, Gualberto

doi:10.1177/15347354211004730

Cited by 19 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A national online cross-sectional survey was conducted between August and September 2021 on one free online platform named Tencent Survey, based upon a similar survey. 3 Prior to the commencement of the survey, it was distributed to a group of experienced oncologists for review, and sent to the integrative physicians of CSIO and their colleagues who were oncologists. Considering this survey was online, open and anonymous to the physicians of CSIO, it could be legally exempt from ethical review after consultation by the ethics committee of the authors.…”

Section: A National Cross-sectional Online Surveymentioning

confidence: 99%

“… 1 , 2 Huge morbidity and mortality requires a holistic approach to cancer care, including conventional cancer treatment and complementary and alternative medicine (CAM). 3 Interest in the use of CAM has grown rapidly in the past 20 years, with 33.3% of US cancer patients using CAM in the past 12 months from the National Health Interview Survey and 40.0% using CAM treatments in China from a national survey. 4 , 5 CAM refers to a group of diverse medical and healthcare interventions, practices, products, or disciplines that are not generally considered as part of conventional medicine, but clearly, the boundaries between CAM and conventional medicine are not absolute.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Basic Characteristics, Status, and Challenges of Integrative Oncology in China

Yang

Zhang

et al. 2021

Integr Cancer Ther

View full text Add to dashboard Cite

Integrative oncology has developed for about 20 years in some countries; however, integrative oncology is still a relative new term for most China’s oncologists. Thus, it is essential to summarize the experience and expertise, share details of differing existing models and discuss future perspectives to help define and guide practice in integrative oncology in China. This study presents a summary of the basic characteristics, status, and challenges of integrative oncology in China, and also reports on China’s integrative physicians’ service delivery, clinical practice and research patterns of integrative oncology by an online national survey, including 405 oncologists. It is easy for cancer patients to access to integrative therapies in China. Public funding is sufficient for integrative oncology in China, and services are often provided through general hospitals and academic hospitals. Most (95.3%) of oncologists showed a positive attitude toward the development of integrative oncology. More than half (55.6%) of the oncologists worried about the influence on integrative oncology of COVID-19, especially for routine treatment, follow-up and holding seminars. We found that integrative oncology in China has swiftly developed in recent years. However, we suggest that standard diagnosis and treatment patterns and national professional guidelines should be set up as soon as possible.

show abstract

Section: A National Cross-sectional Online Surveymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Basic Characteristics, Status, and Challenges of Integrative Oncology in China

Yang

Zhang

et al. 2021

Integr Cancer Ther

View full text Add to dashboard Cite

show abstract

“…It aims to optimize health, quality of life and clinical outcomes across the cancer continuum and to empower people to prevent cancer and become active participants before, during and beyond cancer treatment [ 20 ]. An increasing number of cancer centers in North America [ 21 , 22 , 23 ], Germany [ 24 , 25 ] and Italy [ 26 ] practice IO.…”

Section: Introductionmentioning

confidence: 99%

Impact of Open Dialogue about Complementary Alternative Medicine—A Phase II Randomized Controlled Trial

Stie

Delmar

Nørgaard

et al. 2022

Cancers

View full text Add to dashboard Cite

Complementary alternative medicine (CAM) may reduce the symptom burden of side effects to antineoplastic treatment but also cause new side effects and non-adherence to conventional treatment. The aim of this RCT was to investigate the impact of open dialogue about complementary alternative medicine (OD-CAM) on cancer patients’ safety, health and quality of life (QoL). Patients undergoing antineoplastic treatment were randomly assigned to standard care (SC) plus OD-CAM or SC alone. The primary endpoint was frequency of grade 3–4 adverse events (AE) eight weeks after enrollment. Secondary endpoints were frequency of grade 1–4 AE, QoL, psychological distress, perceived information, attitude towards and use of CAM 12 and 24 weeks after enrollment. Survival was analyzed post hoc. Fifty-seven patients were randomized to the OD-CAM group and fifty-five to the SC group. No significant difference in frequency of grade 3–4 AEs was shown. The same applied to grade 1–4 AEs and QoL, psychological distress and perceived information. A tendency towards better QoL, improved survival and a lower level of anxiety was found in the OD-CAM group. OD-CAM is not superior to SC in reducing the frequency of AEs in patients undergoing antineoplastic treatment. OD-CAM does not compromise patient safety; it may reduce psychological stress and improve QoL and overall survival.

show abstract

“…Well accepted by French oncologists and general practitioners [6], inexpensive [7], it is the complementary medicine most used in supportive care [8]. Homeopathic supportive care is provided in several cancer centres in France and other parts of Europe [9,10] and patient satisfaction rate is very high [8]. Combined with organotherapy and isotherapy, it can form essential supportive care to patients undergoing treatment with the new targeted therapies [11].…”

Section: Introductionmentioning

confidence: 99%

Improving Tolerance and Compliance of New Targeted Therapies with Homeopathy: A Major Challenge in Oncology

BAGOT¹

2022

OBM ICM

Self Cite

View full text Add to dashboard Cite

The application of targeted therapies (TT) in oncology has prolonged survivals and even enabled complete remission of cancers previously considered incurable. With small therapeutic indices, the reduction in dosage or spacing out of the doses of TT due to side effects, represents a significant loss of treatment opportunity for the patients. In the absence of drug interaction and significant side effects, homeopathy used in supportive care improves the quality of life of patients, compliance with oncological treatments and consequently their survival. Based on the author’s clinical experience and published studies, a therapeutic regimen for systematic supportive care of TT is proposed in this study. The originality of the treatment lies in combining a symptomatic diluted and dynamised homeopathic medicine with the patient’s constitutional homeopathic medicine as well as the isotherapeutic agent used for targeted therapy in 7c (10-14). If needs be, the eponymous organotherapy of the organ most affected by the side effects can be added in 4c (10-8). This therapeutic regimen is well accepted and well tolerated. It has been prescribed to approximately 5,000 patients over 25 years including those patients who were given hormone therapy. Facilitating tolerance and acceptance of targeted therapies is very important in oncology in order to fully benefit from the TT efficacy. Homeopathy, organotherapy and isotherapy, by supporting the whole body and treating the major side effects, might improve observance and consequently therapeutic results. Clinical trials could be carried out following the designs and protocols presented in this article.

show abstract

Integrative Oncology: An International Perspective from Six Countries

Cited by 19 publications

References 40 publications

Basic Characteristics, Status, and Challenges of Integrative Oncology in China

Basic Characteristics, Status, and Challenges of Integrative Oncology in China

Impact of Open Dialogue about Complementary Alternative Medicine—A Phase II Randomized Controlled Trial

Improving Tolerance and Compliance of New Targeted Therapies with Homeopathy: A Major Challenge in Oncology

Contact Info

Product

Resources

About